AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow

Phase 3negativevolrustomigNegative

AI Analysis

Summary

AstraZeneca has terminated a late-stage Phase 3 lung cancer trial for volrustomig, though the company will continue development in cervical cancer and mesothelioma indications. This represents a significant clinical setback for the immunotherapy candidate.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Not Met

Outcome Details

Late-stage lung cancer trial terminated

Importance:7/10

Sentiment:

-0.80

trial terminationPhase 3oncologylung cancerclinical setback

Related Companies

$AZN

Read the original article

Published by BioSpace on August 17, 2026 12:11 PM

Read Original